摘要
The decades spanning from the 1940s to the 1960s are renowned as the heyday of antibiotic discovery.It was during this era that game-changing antibiotics such as streptomycin,vancomycin,and tetracycline were unearthed,fundamentally reshaping the landscape of modern medicine.However,antibiotic discovery faces alarming challenges and traditional screening has not yielded new drugs in many decades.The crisis of antimicrobial resistance(AMR)emerges as a consequence of the unintended disruption of the antibiotic discovery pipeline and the subsequent uncontrolled proliferation of resistant pathogens[1].According to the World Health Organization(WHO),in 2019,approximately1.2 million people worldwide died of bacterial infections exacerbated by AMR,surpassing the number of deaths caused by HIV/AIDS.If this trend continues,by 2050,AMR could potentially result in over 10 million deaths,surpassing the mortality rate attributed to cancer.Thus,we are in dire need of new antibiotics to counter the rising resistance of bacteria to most currently employed clinical antibiotics.
作者
李翔
吴敏
帅建伟
Xiang Li;Min Wu;Jianwei Shuai(Department of Physics,and Fujian Provincial Key Lab for Soft Functional Materials Research,Xiamen University,Xiamen 361005,China;Joint Research Centre on Medicine,The Affiliated Xiangshan Hospital of Wenzhou Medical University,Ningbo 315700,China;Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou 325000,China;Oujiang Laboratory(Zhejiang Lab for Regenerative Medicine,Vision and Brain Health),Wenzhou 325001,China)
基金
supported by the Ministry of Science and Technology of China(STI2030-Major Projects 2021ZD0201900)
the National Natural Science Foundation of China(12090052)
the Natural Science Foundation of Fujian Province of China(2023J05002)
the Fundamental Research Funds for the Central Universities(20720230017)
the Affiliated Xiangshan Hospital of Wenzhou Medical University(WIUCASOD2019002)。
